Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ChinaBio Today

18:13 EST 20th November 2017 | BioPortfolio

Here are the most relevant search results for "ChinaBio Today" found in our extensive news archives from over 250 global news sources.

More Information about ChinaBio Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ChinaBio Today for you to read. Along with our medical data and news we also list ChinaBio Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of ChinaBio Today Companies for you to search.

Showing News Articles 1–25 of 325 from ChinaBio Today

Sunday 19th November 2017

Week in Review: Shanghai Pharma Acquires Cardinal's China Drug Distribution Network for $1.2 Billion

Deals and Financings  Shanghai Pharma paid $1.2 billion to win the bidding war for Cardinal Health's China drug distribution operations, making Shanghai Pharma the largest drug distributor in China; Arcus Biosciences, a Bay Area biotech with an in-licensed, China-discovered drug candidate, announced a $107 million financing that included China investors; Adlai Nortye of Hangzhou entered a $8...

Friday 17th November 2017

Adlai Nortye In-Licenses Oncolytic's Cancer Drug in $86.6 Million Deal

Adlai Nortye, a Hangzhou company, entered a $86.6 million iin-licensing agreement to develop and market a novel immuno-oncolytic virus in Greater China that was discovered by Canada's Oncolytics Biotech®. Reolysin® is an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems. Oncolytics plans a US Phase III trial of Reolysin in patients with HR...

Zensun Raises $76 Million for Novel Drug Portfolio

Zensun (Shanghai) Science & Technology raised $76 million from a group of investors led by SDIC Venture Capital Management, which contributed half of the funding itself. Zensun's lead drug is Neucardin™, a novel treatment for chronic heart failure that is aimed at building the heart muscle. Zensun believes the drug, which has completed several Phase II trials in China and the US, will pr...

Ascentage's IND Accepted in US for Inhibitor of Apoptosis Blocker

Ascentage Pharma, a China-US company, reported the US FDA accepted its IND submission to begin clinical trials of APG-1387, a novel small molecule targeting pathways that inhibit apoptosis. Ascentage hopes to test the candidate in patients with advanced solid tumors and hematologic malignancies. If approved for human testing, APG-1387 will be the second of Ascentage's apoptosis-promoting candidate...

Thursday 16th November 2017

Shanghai Pharma Plans to Use M&A to Expand Overseas

Shanghai Pharma told Bloomberg that it wants to keep doing international deals to expand its portfolio of drug offerings. The company plans to acquire specialty drugs from foreign manufacturers, products that target cancer and cardiovascular disorders, along with branded generics from US or European (especially Switzerland or Germany) pharmas. It also hopes to acquire foreign manufacturing facilit...

Shanghai Pharma Acquires Cardinal's China Drug Distribution Business for $1.2 Billion

Shanghai Pharma paid $1.2 billion to win the bidding war for Cardinal Health's China drug distribution operations. Cardinal was China's eighth-largest drug distribution company, with $3.5 billion in 2016 China revenues, while Shanghai Pharma is number three. After the companies are combined, Shanghai Pharma will become number one. In 2010, Cardinal got a foothold in the China market by paying $440...

Wednesday 15th November 2017

CorestoneBio Plans China JV with Boston's Respiratory Motion

Corestone Biosciences, a Beijing novel medical device startup, formed a JV with Respiratory Motion of Boston. The JV will manufacture and offer a new generation of respiratory volume monitors, based on Respiratory Motion's ExSpiron platform, in China and other global markets. The ExSpiron monitors are intended for post-operative hospital care and home use. Founded by industry veterans, CorestoneBi...

Cygnus Raises $19.6 Million for Highly Accurate Sequencing Technology

Cygnus Biosciences, a Beijing company developing a novel sequencing technology, raised $19.6 million in a B Round. Cygnus is built on sequencing breakthroughs that it acquired from a Peking University team. Combining an innovative fluorogenic sequencing method with an information theory error-correction algorithm, Cygnus's technology offers error-free sequences of up to 200 base pairs. The financi...

Tuesday 14th November 2017

RiboQuark Doses First Patient in China siRNA Trial

Kunshan RiboQuark Pharma has dosed the first person in a China trial of a siRNA ocular neuroprotectant therapy. The therapeutic (QPI-1007) treats a "stroke in the eye," known more technically as acute non-arteritic ischemic optic neuropathy (NAION). QPI-1007 temporarily inhibits expression of the apoptotic protein, Caspase 2. RiboQuark is a JV formed by two siRNA companies: Ribo Life Science, head...

Monday 13th November 2017

Pfizer Sells 49% Stake in China-Hisun Generic Drug JV

Pfizer has sold its 49% stake in a China generic drug JV it formed five years ago with Zhejiang Hisun Pharma. The company sold the stake to Sapphire I Holdings at an undisclosed price. In 2016, Pfizer signaled it intended to end the partnership because the JV's profits had not lived up to expectations. In 2012, when the JV was formed, it was said to be worth $545 million, with both companies contr...

Arcus Completes $107 Million C Round with China VC Participation

Arcus Biosciences, a Bay Area biotech, announced a $107 million Series C financing. The round was led by GV (formerly Google Ventures) and included participation from China investors Decheng Capital, BVF Partners and Hillhouse among others. Arcus will use the capital for two clinical programs: AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibody for which Arcus in...

Sunday 12th November 2017

Week in Review: China's Creat to Restructure $1.5 Billion Biotest Takeover

Deals and Financings  China's Creat Group will attempt to restructure its $1.5 billion offer to acquire Biotest, a German blood plasma company, after US regulators nixed the deal; Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to a group that includes China Regenerative Medicine; Zhejiang Huahai Pharma acquired China rights to an immuno-oncology candid...

Saturday 11th November 2017

Valeant Sells Obagi to Fund that Includes China Regenerative Medicine

Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to Haitong International Zhonghua Finance Acquisition Fund I, L.P. and its affiliate Obagi Cosmeceuticals, LLC. Obagi sells cosmeceuticals (skin care products that contain ingredients that have been proven to have a positive effect) through dermatologists or medical spas, although they are OTC products. One of t...

Friday 10th November 2017

Genovis Finds Second China Distribution Partner for Enzyme Portfolio

Genovis, a Swedish enzyme company, signed a China distribution agreement with Shanghai Titan Scientific. Genovis sells a portfolio of enzymes, which it calls SmartEnzymes, that facilitate development and quality control of biological drugs. In September, Genovis announced a distribution pact with Beijing Zhongyuan Ltd., its first foray into the China market. The company sells its products wor...

Ark Biosciences Partners with Calibr on Novel COPD Treatment

Ark Biosciences of Shanghai partnered with the California Institute for Biomedical Research (Calibr) of La Jolla to develop first-in-class therapies for chronic obstructive pulmonary disease and related lung diseases. Based on its breakthrough in synthesizing boronic acids, Calibr constructed a compound to inhibit neutrophil elastase, the cause of damage in COPD, cystic fibrosis and other respirat...

Thursday 9th November 2017

Cellular Biomedicine Opens Shanghai CAR-T Facility

Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park. The company now has three China plants (Beijing, Shanghai, Wuxi), which will provide clinical trial supplies of its CAR-T candidate. In 2015, Cellular Biomedicine formed a partnership with the Chinese PLA General Hospital (the 301 hospital) of

US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest

Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition can not be complete...

Wednesday 8th November 2017

Guangzhou's AnchorDx Raises $28 Million for Precision Oncology Offerings

AnchorDx Corp of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology. The company's major focus applies NGS to methylated circulating tumor DNA (ctDNA) to diagnose early stage cancer. The round was led by 6 Dimensions Capital, the company formed earlier this year by the merger of WuXi Healthcare Ventures and Frontline ...

EOC, an Eddingpharm Spin-out, Closes $32 Million B Round for Oncology Assets

EOC Pharma Group of Shanghai closed a $32 million B funding round. EOC, a spin-out from Eddingpharm, in-licenses rights to develop, manufacture and market oncology assets from global pharmas. Unlike its parent, EOS concentrates on novel oncology drugs that require mid to late stage clinical development for registration. So far, EOC has in-licensed a pipeline of six candidates, which it hopes will ...

Zhejiang Huahai In-licenses Immuno-Oncology Drug in $65 Million Deal

Zhejiang Huahai Pharma acquired Greater China rights to EU-101, a preclinical immuno-oncology candidate discovered by Eutilex of South Korea, in a $65 million agreement. Huahai made a $30 million equity investment into Eutilex, and it will pay up to $35 million in milestones on 10 immuno-oncology indications. Eutilex will also receive royalties on China sales. In an unusual provision, Huahai will ...

Tuesday 7th November 2017

Luye Pharm Leads $11.2 Million Funding of Chicago's Exicure

Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma. Exicure is developing gene silencing and immunotherapeutic drugs using its proprietary three-dimensional Spherical Nucleic Acid (SNA™) constructs to deliver the drug. So far, it has completed a small Phase I trial of a topical psoriasis treatment. Exicure, which previously rece...

Sunday 5th November 2017

Week in Review: Xynomic Signs $502 Million Deal for Boehringer's RAF Inhibitor

Deals and Financings Xynomic Pharma, a US-Shanghai novel drug developer, agreed to pay up to $502 million for global rights to a Boehringer Ingelheim 2nd-gen RAF inhibitor; Japan's Sumitomo Dainippon Pharma announced a $300 million deal to develop Poxel's novel type 2 diabetes drug in Japan, China and other Asian countries; Annoroad, a Beijing genetics services company, raised $100 million in a S...

Saturday 4th November 2017

Guangzhou Pharma May Form China Generics JV with Teva Pharma

Guangzhou Pharma may partner with Teva Pharma, the world's largest generic drugmaker, to form a JV that would bring the Israeli company's generics to China, according to a Bloomberg article. Teva refused to confirm the JV plans, but it didn't deny them either. The two companies already have a relationship: Guangzhou Pharma is awaiting China approval of several Teva generics. Teva does not currentl...

Friday 3rd November 2017

WuXi Biologics Partners with Pall to Reduce mAb Production Costs

WuXi Biologics, a Shanghai CRO/CMO, opened a joint laboratory with Pall Corporation, a filtration/purification specialist, to lower the cost of making monoclonal antibodies by improving continuous processing techniques. The 3-year project aims to lower the cost of manufacturing mAbs significantly -- to $5/g. Initially, the companies will focus on continuous operation of individual processes. Ultim...

Shanghai Fosun To Take Control of Taiwan's Henlix for $98 Million

Shanghai Fosun Pharma will pay up to $98 million to buy the 69% of Henlix Biotech it doesn't already own. Henlix, founded by two US-biopharma veterans in 2010, is a Taiwan-San Francisco innovative biotech that is developing both biosimilars and novel drugs. It has at least four candidates that have either started clinical trials or filed for IND approvals. Fosun will purchase Henlix through its Fo...


Quick Search
Advertisement
 

News Quicklinks